36.15
+1.12%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Locus Cell Co
Its shares trade on Taipei Exchange under the ticker 6891.TWO. It has been listed since 28 April 2022. In the fiscal year to 31 December 2024, it reported revenue of TWD 2.4m and a net loss of TWD 113.0m. At that date it held total assets of TWD 1.82bn and shareholders' equity of TWD 1.72bn.
Locus Cell Co., Ltd. principally engages in the entrusted development and manufacturing of cell therapy-related products. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-04-28. The firm is currently expected to provide cell therapy contract manufacturing organization (CDMO) production and development services using a pilot Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP) facility, with related technologies for cell therapy products (expected to include tissue engineering related products, CAR-T, iPSCs, MSC and other cell therapy applications), process development and process scale-up, analytical method development and validation, clinical GMP manufacturing process for clinical trials, and stability testing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 28 Apr 2022
- Employees
- 32
- Website
- locus-cell.com ↗
Leadership
Pay as last reported
- Mr. Jiunn-Rong ChiouChairman of the Board, since 2024
- Zhicong ZhanChief Financial Officer, Head of Finance, Head of Accounting, Corporate Governance Officer
- Kunying CaiChief Operating Officer, Chief Information Officer
- Yuheng ZhangChief Medical Officer, General Manager, Director, since 2022
- Shi'an ChenDirector
- Mr. Kazuchika FuruishiDirector
- Mr. Linwu KuoDirector
- Junyi WuDirector
- Ms. Bao-Huei HuangIndependent Director
- Guobin LinIndependent Director
- Wenyuan LinIndependent Director
- Mr. Chih-Cheng WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Locus Cell Co Ltd employs 32 full-time employees in Taipei, Taiwan.
- The company provides cell therapy CDMO services using PIC/S GMP facilities.
- Locus Cell Co Ltd focuses on CAR-T, iPSCs, and MSC cell therapy applications.
Weaknesses
- Locus Cell Co Ltd has a small workforce of 32 employees.
- The company's IPO was on 28 April 2022, a recent listing.
- Locus Cell Co Ltd operates in the Health Care sector with limited market presence.
Opportunities
- Locus Cell Co Ltd can expand into tissue engineering related products for cell therapy.
- The company can leverage its PIC/S GMP facility for global CDMO services.
- Locus Cell Co Ltd targets the growing cell therapy market in Taiwan.
Threats
- Locus Cell Co Ltd faces competition from established CDMO providers in the Health Care sector.
- The company's small size may limit its ability to scale rapidly.
- Locus Cell Co Ltd must comply with stringent regulatory requirements in the cell therapy industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.